U.S. FDA approves Lilly migraine drug; price same as rivals

Eli Lilly and Co on Thursday said the U.S. Food and Drug Administration approved its migraine drug Emgality, marking the third approval from a promising new class of treatments for the often debilitating headaches.

from Reuters: Health News https://ift.tt/2Qa6vyG